Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E18.96 EPS (ttm)5.65 Insider Own0.40% Shs Outstand1.51B Perf Week6.35%
Market Cap161.59B Forward P/E10.88 EPS next Y9.85 Insider Trans-23.92% Shs Float1.50B Perf Month19.74%
Income9.41B PEG0.57 EPS next Q2.19 Inst Own87.60% Short Float3.52% Perf Quarter-0.07%
Sales20.70B P/S7.81 EPS this Y10.40% Inst Trans0.12% Short Ratio3.02 Perf Half Y19.22%
Book/sh8.96 P/B11.95 EPS next Y24.71% ROA34.00% Target Price122.58 Perf Year32.86%
Cash/sh4.19 P/C25.58 EPS next 5Y33.42% ROE69.10% 52W Range63.50 - 116.83 Perf YTD13.63%
Dividend- P/FCF16.05 EPS past 5Y11.90% ROI18.70% 52W High-8.32% Beta0.79
Dividend %- Quick Ratio1.80 Sales past 5Y16.00% Gross Margin82.70% 52W Low68.68% ATR3.78
Employees6100 Current Ratio2.10 Sales Q/Q117.10% Oper. Margin58.60% RSI (14)62.82 Volatility2.98% 3.24%
OptionableYes Debt/Eq0.69 EPS Q/Q255.30% Profit Margin45.40% Rel Volume0.58 Prev Close105.54
ShortableYes LT Debt/Eq0.58 EarningsFeb 03 AMC Payout0.00% Avg Volume17.50M Price107.11
Recom1.80 SMA208.24% SMA506.10% SMA20013.58% Volume10,254,600 Change1.49%
Dec-23-14Reiterated Deutsche Bank Buy $142 → $125
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-28-14Reiterated Maxim Group Buy $112 → $127
Jul-24-14Reiterated RBC Capital Mkts Outperform $96 → $102
Apr-28-14Reiterated Maxim Group Buy $101 → $112
Feb-21-14Reiterated Barclays Overweight $90 → $95
Feb-10-14Reiterated Argus Buy $84 → $90
Feb-05-14Reiterated RBC Capital Mkts Outperform $90 → $96
Feb-05-14Reiterated Needham Buy $85 → $95
Feb-05-14Reiterated Maxim Group Buy $98 → $101
Feb-04-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
Jan-28-14Reiterated Deutsche Bank Buy $95 → $132
Jan-06-14Reiterated UBS Buy $80 → $102
Jan-02-14Reiterated Maxim Group Buy $89 → $98
Jan-26-15 02:39PM  PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary Reuters
10:47AM  Gilead Sciences: Time to Worry About a Tough 2015? at Barrons.com
08:31AM  Does Jerseys lagging economy doom Christies bid? at MarketWatch
06:53AM  Regeneron vaults ahead of Amgen in race to market cholesterol drug at Fortune
05:20AM  Gilead to Allow Drug Makers to Produce Hepatitis C Treatment at The Wall Street Journal
02:45AM  Gilead Expands Generic Sovaldi Pact to Add Investigational Pill at Bloomberg
01:00AM  Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent Business Wire
12:00AM  Want To Control Drug Prices? Reject Price Controls at Forbes
Jan-24-15 11:58AM  German insurers win discounts on Gilead's Sovaldi Reuters
Jan-22-15 09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Gilead and Celgene - Press Releases Zacks
04:13AM  US investors double down on biotech bets at Financial Times
Jan-21-15 04:27PM  Deutsche Bank Comments On Concerns Over Consensus Estimates For AbbVie And Gilead Sciences Benzinga
03:13PM  Gilead's John Martin Named Morningstar CEO of 2014 at Barrons.com
01:00PM  Healthcare ETFs in Focus on Mixed JNJ Results - ETF News And Commentary Zacks
01:00PM  Morningstar's 2014 CEO of the Year Morningstar
10:09AM  Podcast: What to Expect From the 4th Quarter Earnings Season Yahoo Finance Contributors
Jan-20-15 04:43PM  The 5 Biggest Biotech Stocks Benzinga
01:44PM  Can Gilead Sciences Beat Hep-C Estimates? at Barrons.com
11:20AM  J&J Earnings Beat But Sales, Guidance Miss at Investor's Business Daily
09:55AM  Cramer's Stop Trading: Biotech hangover CNBC
09:45AM  Johnson & Johnson beats fourth quarter estimates at USA TODAY
Jan-19-15 06:35PM  AbbVie Gains EU Approval for Hepatitis C Virus Treatment - Analyst Blog Zacks
04:04PM  AbbVie's new hepatitis C treatment gets approval in EU AP
08:33AM  Impact Of 'Me-Too' Drugs On Health Care Costs at Forbes
Jan-18-15 01:38PM  Gilead and AbbVie take hepatitis C battle to Europe at Financial Times
11:13AM  Insurers Bullish On Obamacare, Despite Supreme Court Uncertainty at Forbes
08:20AM  Merck Is DJIA Top Stock In 2015 at 24/7 Wall St.
Jan-16-15 05:34PM  Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's AP
05:19PM  CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead's hepatitis C treatment, gets discount Reuters
03:43PM  Aetna Sides With Gilead In Hepatitis C Drug Battle at Investor's Business Daily
03:08PM  Gilead Strikes Another Deal at Barrons.com
10:17AM  Nomura's Takeaways From Meeting With Gilead Sciences' Management Benzinga
05:42AM  Gilead to appeal India patent ruling on hepatitis C drug Reuters
Jan-15-15 07:19PM  Gilead's India patent snag may spur low-cost Sovaldi copies at San Jose Mercury News
02:24PM  How India's Patent Office Destroyed Gilead's Global Game Plan at BusinessWeek
11:02AM  Eli Lilly Has 'Turned The Corner,' Upgraded at Investor's Business Daily
04:59AM  Gileads India Patent Snag May Spur More Low-Cost Sovaldi Copies at Bloomberg
Jan-14-15 09:10PM  India Rejects Gilead Patent Bid for Sovaldi Hepatitis C Treatment at The Wall Street Journal
11:45AM  India rejects Gilead's Hepatitis C drug patent request Reuters
07:55AM  A New Dawn For Biotech? at Forbes
07:23AM  Three platinum stock picks for your portfolio CNBC
Jan-13-15 03:10PM  Stocks Turn Negative; Goodyear Triggers Sell Signal at Investor's Business Daily
02:32PM  Dont look for pricey hepatitis drugs to come down at MarketWatch
01:23PM  The Poster Child For Risk and Reward Yahoo Finance Blogs
12:45PM  Health care's strong 2015 outlook CNBC
10:06AM  Q4 earnings growth leaders & laggards CNBC
Jan-12-15 05:00PM  Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 Business Wire
05:00PM  11 ways to play biotech CNBC
02:00PM  Prime Covers Both Gilead and AbbVie Liver Drugs as Prices Plunge at Bloomberg
09:52AM  Tekmira teams up with OnCore to focus on hepatitis B cure AP
Jan-09-15 05:55PM  Gilead CEO's Latest Sale Totals $14.3M at Barrons.com
01:58PM  Regeneron Can Generate 25% Upside for Investors at Barrons.com
11:49AM  AbbVie Stock Down After Guidance, Downgrade at Investor's Business Daily
11:33AM  UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs Reuters
11:00AM  Gilead Continues to Recover from Express Scripts Loss at 24/7 Wall St.
10:42AM  Gilled Buying Vertex Among Bold Biotech Stock Predictions for 2015 at TheStreet
10:36AM  Fifteen stocks for 2015, part 1 at MarketWatch
09:55AM  Gilead Sciences: Winning at Barrons.com
09:29AM  Macys, Bed Bath & Beyond slump; Gilead gains at MarketWatch
09:08AM  Ahead of the Bell: Drugmaker AbbVie's shares slip AP
09:07AM  What We're Trading Yahoo Finance Blogs
Jan-08-15 05:05PM  Gilead Strikes Hepatitis C Deal With Anthem at Bloomberg
05:03PM  Anthem selects Gilead as primary supplier of hepatitis C drugs Reuters
07:26AM  What A Drug Price Debate Reveals About Obamacare at Forbes
Jan-07-15 05:20PM  Gilead to buy German company's liver disease program for $470 million at bizjournals.com
04:00PM  Mid-cap fund that beats the Street CNBC
11:27AM  Gilead Sciences Just Received Orphan Drug Status For Liver Treatment Benzinga
10:35AM  Analysts 8 Top Health Care Stocks for 2015 at 24/7 Wall St.
10:24AM  Gilead Sciences: A 'Logical' Deal That 'Fits Well' at Barrons.com
Jan-06-15 12:55PM  Midday movers: Chevron, Hess, Morgan Stanley & more at CNBC
12:05PM  Time For a Biotech Pullback? at Barrons.com
11:59AM  Stocks should fall further. Here's why. at CNNMoney.com
11:39AM  Walgreen Year-End Sales Jump On Flu Prescriptions at Investor's Business Daily
11:20AM  Gilead Acquires Drug Program For Fatty Liver Disease at Investor's Business Daily
11:04AM  Cramer: Gilead 'Back in the Driver's Seat' After CVS Deal at TheStreet
10:58AM  Gilead Sciences to buy liver disease treatment from Phenex AP
10:43AM  Will biotech bull run continue? CNBC
10:28AM  The Biotech Stock M&A Guessing Game Yahoo Finance Blogs
10:23AM  Gilead Sciences: Looking Beyond Hepatitis C at Barrons.com
09:28AM  Cramer's Mad Dash: Don't leave biotech CNBC
09:08AM  UPDATE: Barclays Initiates Coverage On Gilead Sciences, 'Should Remain Ahead Of Its Peers' Benzinga
09:02AM  Gilead to Buy Phenex's Liver-Disease Program at The Wall Street Journal
08:38AM  [$$] CVS Gives Preferred Status to Gileads Hepatitis C Drugs at The Wall Street Journal
08:30AM  Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases Business Wire
06:37AM  Pharma pricing wars... who wins? CNBC
Jan-05-15 06:09PM  Gilead hepatitis-C drug wins CVS/Caremark backing at Financial Times
05:45PM  Stock Pops & Drops: HLF, LOCO, URI & GILD CNBC
05:17PM  Gilead makes exclusive deal with CVS for hepatitis C drugs at San Jose Mercury News
05:00PM  7 Ways to play the selloff CNBC
03:52PM  From Ebola To Police Protests Retail Investors Bought The News In 2014 at Forbes
03:10PM  US STOCKS-Energy stocks lead Wall St lower in broad retreat Reuters
03:09PM  CVS Picks Gilead Hep C Drugs As Price War Looms at Investor's Business Daily
02:50PM  Gilead pops, AbbVie drops CNBC
02:35PM  Pharmacy giant CVS opts to exclusively offer Gilead's pricey hepatitis C drug at bizjournals.com
02:22PM  Gilead Sciences: Take That AbbVie! at Barrons.com
02:01PM  Gilead climbs after CVS Health favors its hepatitis C drugs AP
01:05PM  Gilead fights back: CVS deal sends shares soaring at CNBC
12:27PM  CVS Gives Preferred Status to Gilead Hepatitis C Drugs at The Wall Street Journal
10:41AM  Drug pricing concerns? Not at Gilead at CNBC
09:43AM  2015 Biotech Sector Outlook: Bullish but be Wary About Drug Pricing Yahoo Finance Blogs
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Option Exercise16.4070,0001,147,650189,302Jan 20 12:46 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Sale98.4770,0006,893,083119,302Jan 20 12:46 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Option Exercise36.721,00036,72035,308Jan 12 03:55 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Sale100.881,000100,88134,308Jan 12 03:55 PM
MARTIN JOHN CChairman and CEOJan 05Sale96.651009,6654,122,987Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Option Exercise26.995,000134,95020,641Jan 06 02:12 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.095,00095,425120,694Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise14.50150,0002,175,3754,272,987Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Option Exercise40.561,00040,56035,308Jan 06 04:21 PM
Whitley Richard JamesDirectorJan 02Sale95.225,000476,10015,641Jan 06 02:12 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale95.177,000666,192113,694Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Sale95.11149,90014,257,7224,123,087Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Sale95.051,00095,05034,308Jan 06 04:21 PM
Cogan John FrancisDirectorDec 22Option Exercise14.3426,000372,77568,405Dec 24 12:58 PM
Cogan John FrancisDirectorDec 22Sale95.0326,0002,470,75542,405Dec 24 12:58 PM
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM
MILLIGAN JOHN FPresident and COODec 08Sale106.26146,82315,601,122974,048Dec 10 05:32 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise8.01140,6331,125,7674,263,620Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise40.562,00081,12036,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.2931,000752,947149,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Option Exercise26.995,000134,95020,641Dec 03 03:46 PM
MARTIN JOHN CChairman and CEODec 01Sale100.72140,63314,164,8294,122,987Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale100.022,000200,03134,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale100.7933,0003,325,922116,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Sale100.195,000500,96915,641Dec 03 03:46 PM
Cogan John FrancisDirectorNov 21Option Exercise14.3425,000358,43867,405Nov 25 04:10 PM
Cogan John FrancisDirectorNov 21Sale101.2325,0002,530,77042,405Nov 25 04:10 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise8.01146,8951,175,8941,120,943Nov 12 12:48 PM
MILLIGAN JOHN FPresident and COONov 07Sale107.37146,89515,772,736974,048Nov 12 12:48 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000055,832Nov 07 01:20 PM
Carter Paul RutherfordEVP Commercial OpsNov 04Option Exercise0.004,800037,044Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Option Exercise26.995,000134,95020,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Option Exercise8.01140,6251,125,7034,570,012Nov 05 02:05 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Option Exercise40.563,000121,68035,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Option Exercise25.1433,192834,58683,024Nov 05 08:06 PM
Whitley Richard JamesDirectorNov 03Sale112.025,000560,09015,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Sale110.40140,62515,525,1024,429,387Nov 05 02:05 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Sale112.463,000337,38032,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Sale110.2633,1923,659,83749,832Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Option Exercise40.562,00081,12034,244Oct 28 01:35 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Sale110.002,000220,00732,244Oct 28 01:35 PM
Cogan John FrancisDirectorOct 21Option Exercise14.3415,000215,06357,405Oct 23 01:54 PM
Cogan John FrancisDirectorOct 21Sale104.0815,0001,561,14942,405Oct 23 01:54 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Option Exercise40.562,00081,12034,244Sep 30 01:19 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Sale107.472,000214,94532,244Sep 30 01:19 PM
Cogan John FrancisDirectorSep 22Option Exercise14.345,00071,68847,405Sep 24 01:20 PM
Cogan John FrancisDirectorSep 22Sale106.605,000532,98742,405Sep 24 01:20 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
Whitley Richard JamesDirectorJul 01Sale83.655,000418,25015,641Jul 02 04:24 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM
Washington Robin LEVP, CFOJun 30Sale83.9810,400873,40346,774Jul 02 01:44 PM
Cogan John FrancisDirectorJun 23Option Exercise14.345,00071,68847,405Jun 25 01:51 PM
Cogan John FrancisDirectorJun 23Sale81.825,000409,12342,405Jun 25 01:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Option Exercise16.4090,0001,475,550209,302Jun 18 04:33 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Sale80.9090,0007,280,784119,302Jun 18 04:33 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Option Exercise26.9916,728451,48947,433Jun 11 12:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Sale79.4316,7281,328,64530,705Jun 11 12:59 PM
Washington Robin LEVP, CFOJun 04Sale82.526,426530,27457,174Jun 05 05:46 PM
Whitley Richard JamesDirectorJun 02Option Exercise26.995,000134,95020,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Option Exercise23.6031,000731,600161,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Option Exercise8.01140,6251,125,7034,570,012Jun 04 02:48 PM
MARTIN JOHN CChairman and CEOJun 02Sale81.32140,62511,435,8364,429,387Jun 04 02:48 PM